3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Glioma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Neoplasms, Unknown Primary
1
Histiocytic Sarcoma
1
Central Nervous System Neoplasms
1
Interventions
Paclitaxel
6
Carboplatin
6
Gemcitabine
3
pembrolizumab
2
Irinotecan
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
erythromycin propionate-N-acetylcysteinate
1
entrectinib
1
cobimetinib
1
belinostat
1
atezolizumab
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Vemurafenib
1
Surveys and Questionnaires
1
Oxaliplatin
1
HhAntag691
1
Everolimus
1
Etoposide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Unknown Primary
×
ivosidenib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts